Skip to main content

Development, Validation, and Innovation in Ophthalmic Laser-Based Imaging: Report From a US Food and Drug Administration-Cosponsored Forum.

Publication ,  Journal Article
Brodie, F; Repka, M; Burns, SA; Prakalapakorn, SG; Morse, C; Schuman, JS; Duenas, MR; Afshari, N; Pollack, JS; Thorne, JE; Vitale, A; Sen, HN ...
Published in: JAMA Ophthalmol
January 1, 2021

In April 2019, the US Food and Drug Administration, in conjunction with 11 professional ophthalmic, vision science, and optometric societies, convened a forum on laser-based imaging. The forum brought together the Food and Drug Administration, clinicians, researchers, industry members, and other stakeholders to stimulate innovation and ensure that patients in the US are the first in the world to have access to high-quality, safe, and effective medical devices. This conference focused on the technology, clinical applications, regulatory issues, and reimbursement issues surrounding innovative ocular imaging modalities. Furthermore, the emerging role of artificial intelligence in ophthalmic imaging was reviewed. This article summarizes the presentations, discussion, and future directions.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JAMA Ophthalmol

DOI

EISSN

2168-6173

Publication Date

January 1, 2021

Volume

139

Issue

1

Start / End Page

113 / 118

Location

United States

Related Subject Headings

  • United States Food and Drug Administration
  • United States
  • Tomography, Optical Coherence
  • Technology Assessment, Biomedical
  • Risk Factors
  • Risk Assessment
  • Predictive Value of Tests
  • Patient Safety
  • Ophthalmoscopy
  • Ophthalmoscopes
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Brodie, F., Repka, M., Burns, S. A., Prakalapakorn, S. G., Morse, C., Schuman, J. S., … Eydelman, M. (2021). Development, Validation, and Innovation in Ophthalmic Laser-Based Imaging: Report From a US Food and Drug Administration-Cosponsored Forum. JAMA Ophthalmol, 139(1), 113–118. https://doi.org/10.1001/jamaophthalmol.2020.4994
Brodie, Frank, Michael Repka, Stephen Allan Burns, S Grace Prakalapakorn, Christie Morse, Joel S. Schuman, Michael R. Duenas, et al. “Development, Validation, and Innovation in Ophthalmic Laser-Based Imaging: Report From a US Food and Drug Administration-Cosponsored Forum.JAMA Ophthalmol 139, no. 1 (January 1, 2021): 113–18. https://doi.org/10.1001/jamaophthalmol.2020.4994.
Brodie F, Repka M, Burns SA, Prakalapakorn SG, Morse C, Schuman JS, et al. Development, Validation, and Innovation in Ophthalmic Laser-Based Imaging: Report From a US Food and Drug Administration-Cosponsored Forum. JAMA Ophthalmol. 2021 Jan 1;139(1):113–8.
Brodie, Frank, et al. “Development, Validation, and Innovation in Ophthalmic Laser-Based Imaging: Report From a US Food and Drug Administration-Cosponsored Forum.JAMA Ophthalmol, vol. 139, no. 1, Jan. 2021, pp. 113–18. Pubmed, doi:10.1001/jamaophthalmol.2020.4994.
Brodie F, Repka M, Burns SA, Prakalapakorn SG, Morse C, Schuman JS, Duenas MR, Afshari N, Pollack JS, Thorne JE, Vitale A, Sen HN, Myung D, Blumenkranz MS, Tu E, Hammer DX, Tarver M, Cunningham B, Kagemann L, Sadda S, Sarraf D, Jaffe GJ, Eydelman M. Development, Validation, and Innovation in Ophthalmic Laser-Based Imaging: Report From a US Food and Drug Administration-Cosponsored Forum. JAMA Ophthalmol. 2021 Jan 1;139(1):113–118.

Published In

JAMA Ophthalmol

DOI

EISSN

2168-6173

Publication Date

January 1, 2021

Volume

139

Issue

1

Start / End Page

113 / 118

Location

United States

Related Subject Headings

  • United States Food and Drug Administration
  • United States
  • Tomography, Optical Coherence
  • Technology Assessment, Biomedical
  • Risk Factors
  • Risk Assessment
  • Predictive Value of Tests
  • Patient Safety
  • Ophthalmoscopy
  • Ophthalmoscopes